Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
Clinical trial NCT06141226 · RECRUITING
Trial details
- NCT number
- NCT06141226
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-12
- Primary completion
- 2027-12-30
- Enrollment
- 148
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.